Answers are grounded in this paper and cite their sources.
Apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced gastric cancer. Toxicity was consistent with known profiles when given as monotherapy. There was a tendency toward prolonged mPFS and mOS in patients with lymph node metastasis compared with patients with liver metastasis, which could support the need to design a future clinical trial with a better defined patient population.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: